For biopharmaceutical commercial teams, integrating clinical support into Patient Support Programs (PSPs) is becoming a ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

Taiho Pharmaceuticals, together with U.S.-based subsidiary Taiho Oncology, has inched closer to approval of another oral ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Real Chemistry has created an artificial intelligence-enabled platform to improve a manual, fragmented stage of the ...

Injectables juggernaut Fresenius Kabi has been hit with an FDA warning letter, the second for the Fresenius group in less than a month. | The agency raised concerns about contamination and quality ...